Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs
Transmucosal Immediate-Release Fentanyl (TIRF) drugs are a Schedule II controlled substance. Medicare Part D covers TIRF drugs only for managing breakthrough pain in adult cancer patients who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. We will determine whether TIRF drugs were appropriately dispensed in Medicare Part D in accordance with Medicare requirements.
Announced or Revised | Agency | Title | Component | Report Number(s) | Expected Issue Date (FY) |
---|---|---|---|---|---|
Completed | Centers for Medicare and Medicaid Services | Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs | Office of Audit Services | W-00-20-35846; A-09-20-03033 |
2023 |